Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

stiripentol

DIACOMIT

stiripentol (DIACOMIT) is a unknown. Associated with Chiesi Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved Nervous system (N03) N03AX17
US status approved
Patents linked 20
Pipeline programs 3
News articles 0
Drug details — stiripentol
US status
approved
Class
Nervous system (N03)
Route
ORAL
Patents
20
Programs
3
Data quality
0.84
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

stiripentol (DIACOMIT) is a unknown. Associated with Chiesi Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN stiripentol
Brand DIACOMIT
Mechanism Unknown
Therapeutic class Nervous system (N03)
Route ORAL
Formulation CAPSULE
ATC code N03AX17
Originator Chiesi Australia Pty Ltd

Mechanism of action

Unknown

Approval history

Authority Status Date
FDA approved —
EMA approved —
TGA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. STP226 Phase 3 · Biocodex · Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3
  2. STP218 Phase 1 · Biocodex · Dravet syndrome
  3. STP237 Phase 1 · Biocodex · Patients with renal impairement

Related & competitor drugs

Browse all drugs
  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)

Related patents

Browse patents Chiesi Australia Pty Ltd patent hub

  1. WO 2026013310

    COMPOSITION PHARMACEUTIQUE LIQUIDE À BASE DE STIRIPENTOL

    Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2024194388

    PREPARATION DE LEVURE SACCHAROMYCES BOULARDII INACTIVEE

    Expires Wed Sep 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2023046844

    COMPOSITIONS PHARMACEUTIQUES UTILES POUR LA PRÉVENTION OU LE TRAITEMENT D'INFECTIONS VIRALES

    Expires Wed Mar 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. FR 3121841

    Traitement des hyperammoniémies

    Expires Thu Oct 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. EP 3964220

    PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON OSTEOPOROSE

    Expires Tue Mar 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. EP 3485879

    ORALE PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND BAKTERIEN

    Expires Tue May 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. CA 3072544

    SACCHAROMYCES BOULARDII POUR LE TRAITEMENT DES TROUBLES DE L'HUMEUR

    Expires Wed Feb 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. CA 3065417

    TRAITEMENT DE MALADIES ASSOCIEES A UNE DYSREGULATION DE LA VOIE MTOR

    Expires Wed Dec 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. CA 3022447

    COMPOSITION UTILE POUR LA PREPARATION D'UN OVULE

    Expires Wed Oct 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. CA 2951771

    COMPOSITIONS ET METHODES PERMETTANT DE PREVENIR LES INFECTIONS

    Expires Wed Dec 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. FR 3016881

    TRAITEMENT DES DEGENERESCENCES ET DES LESIONS PHOTO-INDUITES DE LA RETINE

    Expires Thu Jul 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. EP 2886116

    Benzodioxol-Derivate zur Verwendung in der Behandlung von Aufmerksamkeitsdefizitstörung und/oder Hyperaktivität

    Expires Tue Jun 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. EP 2875810

    Pharmakologische Behandlung von Zwangsstörungen unter Verwendung von Stiripentol oder einer ähnlichen Verbindung

    Expires Tue May 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. EP 2870969

    Pharmazeutische Zusammensetzung zur Reduzierung der adipösen Masse

    Expires Tue May 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. FR 3005577

    TRAITEMENT DE L'INCONFORT BUCCAL

    Expires Thu Nov 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. FR 2972192

    COMPOSITION PHARMACEUTIQUE DESTINEE A LA PREVENTION OU AU TRAITEMENT DES CANCERS

    Expires Thu Sep 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. CA 2724303

    COMBINAISON SYNERGIQUE DE COMPOSES ANALGESIQUES

    Expires Thu May 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. EP 2229943

    Verbindungen zur Behandlung der peripheren Neuropathie

    Expires Tue Sep 17 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. EP 2201950

    Verbindungen und Verfahren zur Behandlung von autistischen Spektrumsstörungen

    Expires Tue Jun 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. FR 2937553

    COMBINAISON SYNERGIQUE DE COMPOSES ANALGESIQUES

    Expires Thu Apr 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is stiripentol?

stiripentol (DIACOMIT) is a unknown. Associated with Chiesi Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for stiripentol?

DIACOMIT is a marketed brand name for stiripentol. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of stiripentol?

stiripentol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.